Cervical cancer is the second most common leading cause of women's death due to cancer worldwide, about 528,000 patients’ cases and 266,000 deaths per year, related to human papillomavirus (HPV). Peptide-based vaccines being safe, stable, and easy to produce have demonstrated great potential to develop therapeutic HPV vaccine. In this study, the major histocompatibility complex (MHC) class I, class II T cell epitopes of HPV16-E7 were predicted. Therefore, we designed a plan to find the most effective peptides to prompt appropriate immune responses. For this purpose, retrieving protein sequences, conserved region identification, phylogenic tree construction, T cell epitope prediction, epitope-predicted population coverage calculation, and molecular docking were performed consecutively and most effective immune response prompting peptides were selected. Based on different tools index, six CD8+ T cells and six CD4+ epitopes were chosen. This combination of 12 epitopes created a putative global vaccine with a 95.06% population coverage. These identified peptides can be employed further for peptide analysis and can be used as a peptide or poly-epitope candidates for therapeutic vaccine studies to treat HPV-associated cancers.

宫颈癌是全球女性因癌症死亡的第二大常见原因，每年约有 528,000 例患者和 266,000 例死亡与人乳头瘤病毒 (HPV) 相关。基于肽的疫苗安全、稳定且易于生产，已显示出开发治疗性 HPV 疫苗的巨大潜力。在这项研究中，预测了 HPV16-E7 的主要组织相容性复合体 (MHC) I 类、II 类 T 细胞表位。因此，我们设计了一个计划来寻找最有效的肽来促进适当的免疫反应。为此目的，检索蛋白质序列、保守区域识别、系统发育树构建、T 细胞表位预测、表位预测群体覆盖率计算、连续进行分子对接，筛选出最有效的免疫应答提示肽。根据不同的工具指标，选择了6个CD8+ T细胞和6个CD4+表位。这种 12 个表位的组合创造了一种假定的全球疫苗，具有 95.06% 的人口覆盖率。这些已鉴定的肽可进一步用于肽分析，并可用作肽或多表位候选物，用于治疗性疫苗研究以治疗 HPV 相关癌症。